Best MSA Indemnity Architectures for Life Sciences 2026.

01

Mutual indemnity capped at insurance limits

The optimal operator-side structure. Achievable in long-term sponsor relationships and in negotiations led by counsel familiar with industry-standard MSA language.

• - Each party indemnifies the other for claims arising from its own acts or omissions.
• - Indemnity cap aligned to insurance limits ($5M, $10M, or matched to the products tower).
• - Carve-outs for sponsor-supplied materials, sponsor specifications, and sponsor-directed manufacturing changes.
• - Excluded items typically include gross negligence, willful misconduct, IP infringement (handled in a separate IP indemnity clause).

Negotiability: Aggressive but achievable; expect 2-3 rounds of redline.

02

Mutual indemnity with operational carve-outs

Intermediate structure for relationships where the sponsor will not accept indemnity cap at insurance limits but will accept operational carve-outs.

• - Each party indemnifies the other for its own acts, no cap.
• - Carve-outs for sponsor-supplied materials, specifications, regulatory filings, and manufacturing changes the sponsor directed.
• - Effectively shifts the practical liability to insurance limits for the operator because the carve-outs cover the most expensive claim categories.
• - Less protective than capped indemnity but materially better than uncapped one-way.

Negotiability: Moderate; most sponsors will accept this structure with limited redline.

03

One-way indemnity with sponsor-side carve-outs

Structure that emerges when the sponsor refuses to indemnify the operator at all but accepts operator-side carve-outs.

• - Operator indemnifies sponsor for claims arising from operator services; no reciprocal sponsor obligation.
• - Carve-outs for sponsor-supplied materials, sponsor specifications, sponsor-directed changes, sponsor failure to disclose product hazards.
• - The operator's practical exposure is everything outside the carve-outs - the carve-outs do the work that mutual indemnity would do in a balanced contract.
• - Functional but operator-side risk is materially higher than mutual structures.

Negotiability: Common with large pharma sponsors; carve-outs are usually accepted with light redline.

04

Sponsor-only indemnity (rare)

Reverse pattern - sponsor indemnifies operator. Rare; emerges when the operator brings IP, process, or proprietary inputs to the relationship.

• - Sponsor indemnifies operator for claims arising from sponsor instructions, sponsor-supplied materials, or use of the operator's process outside scope.
• - Common in process-licensing arrangements and in operator-led co-development structures.
• - Operator-favorable but requires the operator to bring genuine leverage to the negotiation - typically a differentiated process, regulatory filing, or proprietary technology.

Negotiability: Rare; achievable only with structural leverage.

05

Indemnity escrow / hold-back

Used in M&A-adjacent contracts and in long-term high-value sponsor relationships where indemnity exposure exceeds practical insurance limits.

• - Sponsor holds back a percentage of payments to fund a recoverable indemnity reserve; alternative is sponsor-side parent guarantee or letter of credit.
• - Limits operator's practical exposure to the escrow amount during the hold-back period.
• - Often paired with a survival clause limiting indemnity to a defined post-termination period (2-6 years typical).
• - Common in oncology, gene therapy, and cell therapy CDMO relationships where claim severity outscales standard insurance.

Negotiability: Negotiated as part of commercial deal terms, not as indemnity language per se.